TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors

Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies

(2015) K. L. Berger et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area

(2015) K Sideras et al.   BRITISH JOURNAL OF CANCER

T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice

(2015) Christina Dargel et al.   GASTROENTEROLOGY

Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease

(2015) Neha Nagpal et al.   GENE

Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma

(2015) Li Wang et al.   Hepatobiliary & Pancreatic Diseases International

Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy

(2015) Hirofumi Hanaoka et al.   MOLECULAR PHARMACEUTICS

Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity

(2015) Pavel Skums et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatitis C Genotype Influences Post-liver Transplant Outcomes

(2015) Isabel Campos-Varela et al.   TRANSPLANTATION

Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors

(2015) A. De Luca et al.   Open Forum Infectious Diseases

Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells

(2015) Wei Gao et al.   PLoS One

Next-generation sequencing reveals large connected networks of intra-host HCV variants

(2014) David S Campo et al.   BMC GENOMICS

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

(2014) T. Chodon et al.   CLINICAL CANCER RESEARCH

Characterization of HCV Genotype 5a Envelope Proteins: Implications for Vaccine Development and Therapeutic Entry Target

(2014) Maemu Petronella Gededzha et al.   Hepatitis Monthly

The genetics of hepatitis C virus underlie its ability to escape humoral immunity

(2014) Jay K. Kolls et al.   JOURNAL OF CLINICAL INVESTIGATION

CD4 T Cells Specific for a Latency-Associated γ-Herpesvirus Epitope Are Polyfunctional and Cytotoxic

(2014) Michael L. Freeman et al.   JOURNAL OF IMMUNOLOGY

A Novel Murine T-Cell Receptor Targeting NY-ESO-1

(2014) Shannon F. Rosati et al.   JOURNAL OF IMMUNOTHERAPY

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Michael Manns et al.   LANCET

Tumor-associated antigen specific CD8+T cells in hepatocellular carcinoma – a promising target for immunotherapy

(2014) Nathalie Schmidt et al.   OncoImmunology

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma

(2013) Tobias Flecken et al.   HEPATOLOGY

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

(2013) Richard A. Morgan et al.   JOURNAL OF IMMUNOTHERAPY

Lack of variant specific CD8+ T-cell response against mutant and pre-existing variants leads to outgrowth of particular clones in acute hepatitis C

(2013) Axel Ulsenheimer et al.   Virology Journal

Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients

(2013) S. Kitano et al.   Cancer Immunology Research

TCR-Redirected Human T Cells Inhibit Hepatitis C Virus Replication: Hepatotoxic Potential Is Linked to Antigen Specificity and Functional Avidity

(2012) Anna Pasetto et al.   JOURNAL OF IMMUNOLOGY

EBV Latency II-derived Peptides Induce A Specific CD4+ Cytotoxic T-cell Activity and Not A CD4+ Regulatory T-cell Response

(2012) Olivier Moralès et al.   JOURNAL OF IMMUNOTHERAPY

Characterization of CD4+ Cytotoxic Lymphocytes and Apoptosis Markers Induced by Trypanossoma cruzi Infection

(2012) T. S. L. Keesen et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection

(2011) Matthew F. Cusick et al.   HUMAN IMMUNOLOGY

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting

(2010) Håkan Norell et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

(2010) Paul Y Kwo et al.   LANCET

Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity

(2010) Yi Zhang et al.   PLoS Pathogens

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural history of hepatitis-related hepatocellular carcinoma

(2008) David-Yiu-Kuen But   WORLD JOURNAL OF GASTROENTEROLOGY